Bio-Rad Laboratories, Inc.
BIO
$281.02
-$9.84-3.38%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 681.18M | 632.12M | 681.11M | 676.84M | 730.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 681.18M | 632.12M | 681.11M | 676.84M | 730.29M |
| Cost of Revenue | 314.82M | 296.44M | 318.63M | 314.13M | 332.09M |
| Gross Profit | 366.36M | 335.68M | 362.48M | 362.72M | 398.20M |
| SG&A Expenses | 206.65M | 201.00M | 207.52M | 216.45M | 209.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 584.17M | 540.98M | 591.19M | 601.33M | 607.22M |
| Operating Income | 97.02M | 91.15M | 89.92M | 75.51M | 123.07M |
| Income Before Tax | 428.39M | 137.10M | -1.50B | 84.83M | 1.09B |
| Income Tax Expenses | 78.68M | 30.85M | -338.18M | 15.87M | 263.55M |
| Earnings from Continuing Operations | 349.71M | 106.26M | -1.16B | 68.96M | 827.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 349.71M | 106.26M | -1.16B | 68.96M | 827.73M |
| EBIT | 97.02M | 91.15M | 89.92M | 75.51M | 123.07M |
| EBITDA | 134.22M | 128.45M | 125.72M | 111.11M | 158.57M |
| EPS Basic | 12.15 | 3.65 | -39.59 | 2.33 | 27.89 |
| Normalized Basic EPS | 2.26 | 2.16 | 2.04 | 2.46 | 2.65 |
| EPS Diluted | 12.13 | 3.64 | -39.59 | 2.32 | 27.78 |
| Normalized Diluted EPS | 2.25 | 2.16 | 2.04 | 2.45 | 2.64 |
| Average Basic Shares Outstanding | 28.79M | 29.10M | 29.36M | 29.60M | 29.68M |
| Average Diluted Shares Outstanding | 28.82M | 29.22M | 29.36M | 29.75M | 29.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
